---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-024121"
form_type: "8-K"
ticker: "NXTC"
cik: "0001661059"
company_name: "NextCure, Inc."
filed_at: "2026-03-05T23:59:59+00:00"
generated_at: "2026-05-15T19:42:10.410862+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# NextCure reports FY2025 net loss of $55.8M; cash $41.8M; SIM0505 data expected Q2 2026

## Summary
- Cash, cash equivalents and marketable securities at Dec 31, 2025: $41.8M, down from $68.6M a year ago.
- Net loss for FY2025: $55.8M, roughly flat vs $55.7M in FY2024; R&D expenses rose to $44.9M.
- SIM0505 (CDH6 ADC) Phase 1 dose escalation data and dose optimization start in ovarian cancer both expected Q2 2026.
- LNCB74 (B7-H4 ADC) Phase 1 dose escalation update anticipated in second half of 2026.
- Company expects current resources to fund operations into first half of 2027 through proof-of-concept for SIM0505.

## SEC filing metadata
- accession: 0001104659-26-024121
- form_type: 8-K
- ticker: NXTC
- cik: 0001661059
- company_name: NextCure, Inc.
- filed_at: 2026-03-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1661059/000110465926024121/0001104659-26-024121-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1661059/000110465926024121/nxtc-20260305x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-024121
- JSON: https://secwatch.observer/filing/0001104659-26-024121.json
- Plain text: https://secwatch.observer/filing/0001104659-26-024121.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.